Loading…
Loading…
EQUITY / NASDAQ · XNCM
TransCode Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.57 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.57 USD · Volume 15,511
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -6,789,505 USD | -4,221,134 USD | — |
| Net income | -6,750,128 USD | -4,276,502 USD | — |
| Cash and cash equivalents | 8,383,393 USD | — | — |
| Total liabilities | 12,651,920 USD | — | — |
| Total equity | -27,694,917 USD | 6,147,706 USD | -550.49% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,383,393 USD | — | — | 17,813,521 USD | 17,813,521 USD | 2,835,916 USD | — | — |
| Net incomeIncome statement | -6,750,128 USD | -24,535,198 USD | -17,785,071 USD | — | -34,661,076 USD | -4,856,051 USD | -21,217,966 USD | -4,276,502 USD |
| Operating profitIncome statement | -6,789,505 USD | -24,544,533 USD | — | — | -27,980,071 USD | -4,561,200 USD | -11,953,514 USD | -4,221,134 USD |
| Total assetsBalance sheet | 151,010,103 USD | — | — | 162,398,689 USD | 162,398,689 USD | 5,226,682 USD | — | — |
| Total equityBalance sheet | -27,694,917 USD | — | 1,251,427 USD | 10,335,466 USD | 10,335,466 USD | 1,425,979 USD | — | 6,147,706 USD |
| Total liabilitiesBalance sheet | 12,651,920 USD | — | — | 10,518,687 USD | 10,518,687 USD | 3,800,703 USD | — | — |
| Financing cash flowCash flow statement | — | 950,000 USD | — | — | 31,523,122 USD | — | 8,399,071 USD | — |
| Operating cash flowCash flow statement | — | -10,380,128 USD | — | — | -19,516,229 USD | — | -11,374,219 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 6,660 USD | — | — | — |
| Investing cash flowCash flow statement | — | — | — | — | -4,436 USD | — | — | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 04/15/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.